<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40198">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01924923</url>
  </required_header>
  <id_info>
    <org_study_id>NBT-01</org_study_id>
    <nct_id>NCT01924923</nct_id>
  </id_info>
  <brief_title>New Biopsy Technique for Uveal Melanoma</brief_title>
  <official_title>New Biopsy Technique for Uveal Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Greater Houston Retina Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Methodist Hospital System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Greater Houston Retina Research</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study intends to investigate a new biopsy technique that will decrease the
      incidence of tumor cells in the biopsy tract.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Uveal melanoma is the most common primary malignancy of the eye and is one of the few fatal
      diseases that are detected initially through an eye examination. For many years, clinical
      decision-making regarding which patient with uveal melanoma required treatment has been
      based solely on clinical features observed at the time of diagnosis. These features include:
      tumor size as measured by ultrasound, associated subretinal fluid, presence of orange
      lipofuscin pigment, lack of drusen, posterior location, and ciliary body involvement. All of
      these clinical features have been demonstrated to be associated with tumor growth which is
      associated with the eventual development of metastases. However, these clinical features are
      not adequately sensitive or specific enough to predict which patients will develop
      metastases.

      More recently, researchers studying the genomics of uveal melanoma have focused on
      identifying genetic abnormalities present in tumor tissue in order to characterize these
      lesions more fully. Several landmark papers over the past 15 years have reported cytogenic
      and genomic abnormalities in uveal melanoma tumor tissue that are associated with a poorer
      prognosis. Although rare, there have been at least five cases in which patients undergoing
      biopsy of these lesions have developed extraocular spread of melanoma from the biopsy sites.
      With this new technique, the possible rate of extraocular spread should be lower, making the
      biopsy a safer technique than what is currently in practice.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Number of subjects with melanotic cells present at biopsy needle site</measure>
    <time_frame>1 Year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Uveal Melanoma</condition>
  <arm_group>
    <arm_group_label>Uveal Melanoma</arm_group_label>
    <description>Scheduled for enucleation surgery</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The eye will be enucleated and histopathologic sections of the sclera will be examined for
      extra scleral extension of cells. After the tissues are examined, they will be stored in the
      ocular histopathology lab for 10 years.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients over 21, diagnosed with uveal melanoma and scheduled to undergo enucleation
        surgery. No known metastatis.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with uveal melanoma

          -  Scheduled for enucleation surgery

        Exclusion Criteria:

          -  Patients under 21 years old

          -  Patients unable to undergo surgery

          -  Patients with known metastatic uveal melanoma or other cancer.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy C. Schefler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retina Consultants of Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retina Consultants of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Kao</last_name>
      <phone>713-394-7547</phone>
      <email>leslie.kao@houstonretina.com</email>
    </contact>
    <contact_backup>
      <last_name>Karri Schuetzle</last_name>
      <phone>713-394-7534</phone>
      <email>karri.schuetzle@houstonretina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Amy C Schefler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patricia Chevez-Barrios, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>[No authors listed] The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma III: local complications and observations following enucleation COMS report no. 11. Am J Ophthalmol. 1998 Sep;126(3):362-72.</citation>
    <PMID>9744369</PMID>
  </reference>
  <reference>
    <citation>[No authors listed] The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma II: initial mortality findings. COMS report no. 10. Am J Ophthalmol. 1998 Jun;125(6):779-96.</citation>
    <PMID>9645716</PMID>
  </reference>
  <reference>
    <citation>Schyberg E. Fine needle biopsy of orbital tumours [proceedings]. Acta Ophthalmol Suppl. 1975;(125):11.</citation>
    <PMID>184645</PMID>
  </reference>
  <reference>
    <citation>Jakobiec FA, Coleman DJ, Chattock A, Smith M. Ultrasonically guided needle biopsy and cytologic diagnosis of solid intraocular tumors. Ophthalmology. 1979 Sep;86(9):1662-81.</citation>
    <PMID>551354</PMID>
  </reference>
  <reference>
    <citation>Caminal JM, Sanz S, Carreras M, Catal√† I, Arruga J, Roca G. Epibulbar seeding at the site of a transvitreal fine-needle aspiration biopsy. Arch Ophthalmol. 2006 Apr;124(4):587-9.</citation>
    <PMID>16606890</PMID>
  </reference>
  <reference>
    <citation>Glasgow BJ, Brown HH, Zargoza AM, Foos RY. Quantitation of tumor seeding from fine needle aspiration of ocular melanomas. Am J Ophthalmol. 1988 May 15;105(5):538-46.</citation>
    <PMID>3369520</PMID>
  </reference>
  <reference>
    <citation>Karcioglu ZA, Gordon RA, Karcioglu GL. Tumor seeding in ocular fine needle aspiration biopsy. Ophthalmology. 1985 Dec;92(12):1763-7.</citation>
    <PMID>4088631</PMID>
  </reference>
  <reference>
    <citation>Engzell U, Esposti PL, Rubio C, Sigurdson A, Zajicek J. Investigation on tumour spread in connection with aspiration biopsy. Acta Radiol Ther Phys Biol. 1971 Aug;10(4):385-98.</citation>
    <PMID>4329702</PMID>
  </reference>
  <reference>
    <citation>SNELL AC Jr. Heterotransplantation of tumors into various regions of the guinea-pig eye. Am J Ophthalmol. 1951 May;34(5 1):733-8.</citation>
    <PMID>14829489</PMID>
  </reference>
  <reference>
    <citation>Shields JA, Shields CL, Ehya H, Eagle RC Jr, De Potter P. Fine-needle aspiration biopsy of suspected intraocular tumors. The 1992 Urwick Lecture. Ophthalmology. 1993 Nov;100(11):1677-84.</citation>
    <PMID>8233394</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 18, 2014</lastchanged_date>
  <firstreceived_date>August 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Greater Houston Retina Research</investigator_affiliation>
    <investigator_full_name>Amy C Schefler, MD</investigator_full_name>
    <investigator_title>Director of Ophthalmic Oncology</investigator_title>
  </responsible_party>
  <keyword>uveal melanoma</keyword>
  <keyword>biopsy</keyword>
  <keyword>enucleation</keyword>
  <keyword>ocular cancer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
